Rheumatoid Arthritis
From synovial biology to treat-to-target โ the definitive board-ready module
Rheumatoid Arthritis (RA) is the most common form of chronic inflammatory arthritis, affecting approximately 0.5โ1% of adults worldwide, with a global burden of ~18 million people. Per StatPearls 2023 / Harrison’s 21e.
Global Burden
- Prevalence varies geographically โ Native American tribes (Pima, Chippewa) report rates up to 7%; Asia and Africa have lower rates (0.2โ0.4%)
- India: Estimated prevalence ~0.75% (~10 million affected); often presents late due to limited awareness
- Incidence has remained relatively stable but disability burden has decreased due to modern DMARDs
- More common in females โ thought to be estrogen-mediated immune dysregulation
- In some Latin American and African countries, female:male ratio reaches 6:1
Why RA Matters Clinically
- ๐ด Leading cause of inflammatory joint destruction โ up to 50% of patients have significant disability within 10 years if undertreated
- ๐ด Systemic disease โ extraarticular manifestations affect multiple organs; cardiovascular mortality 2ร general population
- ๐ก Median life expectancy shortened by 7 years (men) and 3 years (women)
- ๐ข Completely reversible if diagnosed early and treated aggressively โ “Treat-to-Target” revolution has transformed outcomes
-
L1REMEMBER โ Define RA and recall its epidemiology, demographics, and the 2010 ACR/EULAR classification criteria components
-
L2UNDERSTAND โ Explain the molecular pathogenesis of RA including the role of CD4+ T cells, B cells, TNF-ฮฑ, IL-6, and pannus formation in joint destruction
-
L3APPLY โ Construct a diagnostic algorithm for a patient presenting with symmetrical polyarthritis, applying classification criteria and appropriate investigations
-
L4ANALYZE โ Differentiate RA from other inflammatory arthritides using clinical, serological, imaging, and histological data
-
L5EVALUATE โ Formulate a EULAR 2025 guideline-aligned treatment plan for early, established, and refractory RA including special populations
-
L6CREATE โ Design a comprehensive monitoring strategy incorporating disease activity scores (DAS28/CDAI/SDAI), drug toxicity surveillance, and a Treat-to-Target approach with patient counseling
After completing this module you will confidently diagnose RA in the clinic, score disease activity at the bedside, sequence DMARDs per 2025 EULAR guidance, counsel patients on methotrexate, biologics, and JAK inhibitors, and identify life-threatening extraarticular complications โ putting you in the top 5% of medical graduates globally on this topic.
RA is a multifactorial disease with heritability estimated at 40โ65%. Genetic factors account for ~50% of the risk in ACPA-positive RA.
HLA-DRB1 โ The Shared Epitope (SE)
The strongest genetic association is with MHC Class II alleles, particularly HLA-DRB1. The SE is a conserved amino acid sequence (positions 70โ74) in the third hypervariable region of the HLA-DR ฮฒ-chain. Per Harrison’s 21e, Chapter 358.
- SE alleles: HLA-DRB1*0401, *0404, *0101 (European); *0405, *0901 (Asian)
- The SE promotes peptide binding and T-cell activation โ particularly citrullinated peptides
- Carriers of 2 SE alleles have much higher disease risk and worse outcomes than 1 or no SE
Non-HLA Genetic Loci (GWAS Discoveries)
- PTPN22 โ Encodes lymphoid tyrosine phosphatase; gain-of-function โ impaired self-tolerance; common in Europeans
- PADI4 โ Encodes PAD4 enzyme; converts arginine โ citrulline; strongly associated with ACPA+ RA in East Asians
- TNFAIP3 / TRAF1-C5 / CTLA4 โ B-cell and T-cell signaling pathways
- STAT4 / BTLA / ELMOI โ Cytokine and cell migration regulation
- Cigarette Smoking โ Most reproducible environmental risk; 1.5โ3.5ร increased RA risk; synergizes with SE alleles up to 40-fold; activates PAD enzymes in lung โ citrullination โ ACPA generation
- Periodontitis / P. gingivalis โ Only oral bacterium expressing PAD enzyme โ generates citrullinated antigens โ may initiate ACPA response years before joint symptoms
- Gut microbiome โ Dysbiosis (โ Prevotella copri in early RA); exact mechanism unclear
- Epigenetic factors โ DNA methylation differences between RA and OA patients; miR146a implicated in synovial fibroblast activation
| Cytokine | Key Actions in RA | Therapeutic Target |
|---|---|---|
| TNF-ฮฑ | Upregulates adhesion molecules, stimulates IL-1/IL-6/MMP; central amplifier | Anti-TNF biologics (adalimumab, etanercept, infliximab, etc.) |
| IL-6 | Acute phase response (CRPโ), synovitis, anemia, T/B cell differentiation, osteoclast activation | Tocilizumab, Sarilumab (IL-6R inhibitors) |
| IL-1 | Cartilage catabolism, fever, MMP induction | Anakinra (IL-1RA) |
| IL-17 | Neutrophil recruitment, RANKL upregulation, synovitis | Secukinumab (NOT approved for RA; more for SpA) |
| GM-CSF | Monocyte/macrophage differentiation, inflammation amplification | Under investigation |
| RANKL | Osteoclast differentiation โ bone erosions | Denosumab (adjunct for osteoporosis in RA) |
| JAK/STAT pathway | Intracellular signaling for multiple cytokines (IL-6, IL-12, IL-23, IFN-ฮณ) | JAK inhibitors (tofacitinib, baricitinib, upadacitinib) |
- The “shared epitope” is in HLA-DRB1 at positions 70โ74 of the ฮฒ-chain โ critical for peptide presentation
- PADI4 encodes the enzyme that citrullinates proteins โ the molecular basis of ACPA
- Smoking confers 40ร risk when combined with SE alleles โ the strongest gene-environment interaction in RA
- RF is not specific โ also +ve in SLE, Sjรถgren’s, chronic infections; ACPA is specific (~97%)
- The pannus is invasive fibrovascular tissue from the synovium that directly destroys cartilage and bone
- DKK-1 (upregulated by TNF) blocks Wnt signaling โ suppresses osteoblasts โ bone cannot regenerate after erosion
A 42-year-old female presents with a 3-month history of swelling and pain in both hands, affecting the MCPs and PIPs symmetrically, with morning stiffness lasting 2 hours that improves with activity. She notices her grip has weakened โ she now struggles to open jar lids. On examination: boggy synovitis of bilateral MCPs, ulnar deviation of fingers, positive squeeze test. ESR 78 mm/hr, CRP 42 mg/L, RF 1:320, Anti-CCP positive. This is RA until proven otherwise.
| Joint | Pattern | Classic Deformity / Feature |
|---|---|---|
| MCP joints | Early, bilateral, symmetric | Volar subluxation + ulnar deviation |
| PIP joints | Bilateral, early | Swan-neck (PIP hyperextension, DIP flexion) or Boutonniรจre (PIP flexion, DIP hyperextension) |
| Wrists | Very frequent; “caput ulnae” | Subluxation, carpal tunnel, piano-key sign |
| MTP joints | Feet โ lateral aspect of 5th MTP first | “Cock-up” deformities; subluxation, calluses |
| Knee | Synovial effusion common | Baker’s cyst (popliteal); can rupture โ DVT mimic ๐ฉ |
| Cervical spine (C1-C2) | Atlantoaxial subluxation | ๐ด Cord compression risk โ check BEFORE intubation |
| DIP joints | Typically spared (unlike OA/PsA) | Involvement suggests PsA or OA |
| Lumbar/thoracic spine | Typically spared | Involvement suggests SpA |
EAMs more common in patients with: high-titre RF/ACPA, heavy smoking history, severe joint disease, early onset, male sex. Subcutaneous nodules = high-RF patient. ILD = smoker + high RF.
| System | Manifestation | Notes / High-Yield |
|---|---|---|
| Skin | Rheumatoid nodules (30โ40%), purpura, pyoderma gangrenosum | Nodules at pressure points; can occur in lungs/pleura (Caplan’s syndrome with pneumoconiosis) |
| Pulmonary | Pleural effusions, ILD (UIP/NSIP), pulmonary nodules, pulmonary vasculitis, organizing pneumonia | ILD prevalence 3โ12%; can precede arthritis; screen with HRCT. Leflunomide/MTX can worsen ILD ๐ด |
| Cardiovascular | Pericarditis, myocarditis, CAD (2รโ), cardiomyopathy, mitral regurgitation | ๐ด #1 cause of death in RA is cardiovascular disease |
| Ocular | KCS (2ยฐ Sjรถgren’s), episcleritis, scleritis | Scleromalacia perforans = painless blue-grey thinning โ perforation risk |
| Neurological | Peripheral neuropathy, mononeuritis multiplex, cervical myelopathy (C1-C2) | Atlantoaxial subluxation โ Lhermitte’s sign; check before GA |
| Haematological | Anaemia of chronic disease (#1), thrombocytosis, neutropenia, Felty’s syndrome, T-LGL | Felty’s = RA + splenomegaly + neutropenia ๐ก (Triad) |
| Renal | Membranous nephropathy, secondary amyloidosis (AA amyloid) | Drug toxicity (NSAIDs, gold) also common renal issues |
| Endocrine | Hypoandrogenism in males | Low testosterone correlates with disease activity |
| GI | Vasculitis | Rare; suggests active systemic disease |
| Lymphoma | 2โ4ร increased risk (diffuse large B-cell) | Risk โ with Felty’s syndrome and high disease activity |
| Sjรถgren’s (2ยฐ) | Xerostomia (dry mouth) + KCS (dry eyes) โ 10% of RA | Distinguish from 1ยฐ Sjรถgren’s |
| Vasculitis | Cutaneous (palpable purpura, ulcers, nail fold infarcts), mononeuritis multiplex | Decreasing incidence with modern DMARDs; suggests severe disease |
- ๐ด Fever >38.3ยฐC in RA patient โ Think INFECTION first (septic arthritis, opportunistic), not flare
- ๐ด Neck pain with myelopathy signs (upper limb weakness, Lhermitte’s) โ Atlantoaxial subluxation โ URGENT imaging
- ๐ด Acute red eye with photophobia โ Scleritis not conjunctivitis; vision-threatening
- ๐ด Progressive dyspnoea on exertion in RA patient โ ILD / pericardial effusion / pulmonary hypertension
- ๐ด Hot, red, swollen single joint in RA โ Septic arthritis until proven otherwise (aspirate immediately)
- ๐ด Calf swelling after knee flare โ Ruptured Baker’s cyst mimics DVT โ ultrasound mandatory
- Morning stiffness >1 hour = inflammatory; <30 min = OA
- RA involves MCPs and PIPs but SPARES DIPs (unlike OA); SPARES SI joints (unlike SpA)
- Felty’s syndrome = RA + splenomegaly + neutropenia โ โlymphoma risk
- Most common cause of death in RA = Cardiovascular disease (not infection)
- Atlantoaxial subluxation occurs in <10% of patients now (down from 20โ30% in pre-DMARD era)
- ILD precedes arthritis in some patients โ seronegative does NOT mean no ILD risk
Per EULAR 2025: Classification criteria are for research, not diagnosis. Diagnosis is clinical. A patient can have RA with <6 points if the rheumatologist judges clinical synovitis is present.
| Domain | Finding | Score |
|---|---|---|
| A. Joint Involvement (swollen or tender) | 1 large joint (shoulder, elbow, hip, knee, ankle) | 0 |
| 2โ10 large joints | 1 | |
| 1โ3 small joints (MCP, PIP, MTP, wrist, 2nd-5th MTP) | 2 | |
| 4โ10 small joints | 3 | |
| >10 joints (at least 1 small joint) | 5 | |
| B. Serology | Negative RF AND negative ACPA | 0 |
| Low positive RF OR low positive ACPA (<3ร ULN) | 2 | |
| High positive RF OR high positive ACPA (โฅ3ร ULN) | 3 | |
| Anti-CCP preferred over RF for specificity | ||
| C. Acute Phase Reactants | Normal CRP AND normal ESR | 0 |
| Abnormal CRP OR abnormal ESR | 1 | |
| D. Duration of Symptoms | <6 weeks | 0 |
| โฅ6 weeks | 1 | |
| ๐ข Score โฅ6/10 = Definite RA | Max: 10 | |
Note: Applies to patients with โฅ1 clinically swollen joint not better explained by another diagnosis. Source: Aletaha D et al, Arthritis Rheum 2010.
| Modality | Key Findings | Sensitivity / Specificity | Clinical Use |
|---|---|---|---|
| X-ray (plain radiograph) | Periarticular osteopenia, soft tissue swelling (early); erosions, joint space narrowing, subluxation (late) | Low sensitivity for early disease (~25%) | First-line; monitoring progression; diagnostic late |
| Ultrasound (Power Doppler) | Synovial thickening, joint effusion, tenosynovitis, early erosions, vascularity (active inflammation) | More sensitive than X-ray for synovitis and early erosions | Bedside, no radiation; evaluate response to treatment; guide injection |
| MRI | Bone marrow oedema (pre-erosive!), synovitis, tenosynovitis, erosions (best visualization) | Gold standard for early erosion detection; Spec ~80โ90% | Early disease when X-ray negative; cervical spine (C1โC2 stability) |
| CT | Lung (HRCT for ILD โ UIP, NSIP patterns), erosions in small bones | Gold standard for ILD characterization | Pulmonary complications; surgical planning |
- ๐ก RF negative in ~30% of RA โ “seronegative RA” is still RA if other criteria met; check anti-CCP
- ๐ก Anti-CCP appears 10+ years before symptoms โ highly predictive of RA development in at-risk individuals
- ๐ก RF positive in many other conditions: SLE, Sjรถgren’s, HCV, SBE, TB, Waldenstrรถm’s, normal elderly โ do NOT diagnose RA on RF alone
- ๐ก Synovial fluid in RA: WBC 2,000โ50,000/ฮผL (inflammatory); predominantly PMN neutrophils; glucose mildly low; complement low
- ๐ก ESR/CRP interpretation with IL-6 inhibitors and JAKi โ CRP is markedly suppressed independently of clinical response; use joint counts (DAS28-CRP may be falsely low)
- ๐ก Anti-CCP + RF together: If both positive, specificity for RA approaches 99%
- Anti-CCP specificity = ~97% โ most specific test in RA
- Score โฅ6/10 on 2010 ACR/EULAR = Definite RA
- MRI detects bone marrow oedema before erosions form โ the earliest structural warning sign
- Power Doppler US: vascularity = active synovitis; guides injection and treatment decisions
- Seronegative RA = RF and anti-CCP both negative in ~10% of RA patients
| Condition | Similarities to RA | Key Distinguishing Features | Clincher Test |
|---|---|---|---|
| Osteoarthritis (OA) | Joint pain, stiffness | Morning stiffness <30 min; affects DIPs (Heberden’s) and 1st CMC; bony swelling; no systemic features; normal CRP/ESR | X-ray: osteophytes, sclerosis (no erosions) |
| Psoriatic Arthritis (PsA) | Polyarthritis, RF may be negative | DIP involvement; “sausage digits” (dactylitis); enthesitis; psoriatic skin/nail changes; often seronegative; asymmetric; sacroiliitis | Skin/nail examination; X-ray: “pencil in cup” deformity; SI joint imaging |
| SLE Arthritis | Symmetrical small joint polyarthritis, positive ANA | Jaccoud’s arthropathy (reducible โ ligament laxity, not erosive); rash (malar, photosensitive); multi-organ; anti-dsDNA, low C3/C4 | Anti-dsDNA (specific for SLE); complement levels; urinalysis |
| Reactive Arthritis (ReA) | Acute joint swelling, young adults | Follows infection (GI or urogenital); asymmetric; large joints; Reiter’s triad: urethritis + conjunctivitis + arthritis; self-limiting; HLA-B27 positive | Preceding infection history; HLA-B27; STI/GI culture |
| Gout / Pseudogout | Joint swelling, pain | Episodic, asymmetric; gout = MTP-1 (podagra), uric acid crystals; pseudogout = large joints (knee), chondrocalcinosis on X-ray; serum uric acid (not diagnostic alone) | ๐ด JOINT ASPIRATION โ MSU crystals (needle, negatively birefringent) or CPPD crystals (rhomboid, weakly +ve birefringent) |
| Polymyalgia Rheumatica (PMR) | Elderly, stiffness, elevated ESR/CRP, RF can be low-positive | Age >50; proximal girdle (shoulder, hip) stiffness; NO small joint synovitis; dramatic response to low-dose prednisolone; associated GCA | Age, proximal pattern, dramatic response to prednisone 15โ20 mg/day |
| Viral Arthritis | Symmetrical polyarthritis, RF+ possible | Parvovirus B19: “slapped cheek” rash, transient (<6 weeks); HCV: chronic, low-titre RF; Rubella; Chikungunya (epidemic, acute) | Serology (anti-B19 IgM, HCV PCR); symptoms usually resolve |
- ๐ด Septic Arthritis โ A hot, swollen joint in an RA patient on DMARDs/biologics is infected until proven otherwise. Aspirate immediately. Delay = joint destruction + sepsis
- ๐ด Malignancy โ Paraneoplastic arthritis can mimic RA. In seronegative elderly with atypical features, consider lymphoma, solid tumours
- ๐ด RS3PE Syndrome โ Remitting, seronegative symmetric synovitis with pitting oedema; elderly males; responds to low-dose prednisone; rule out underlying malignancy
- ๐ด Adult-onset Still’s disease (AOSD) โ Quotidian fever + salmon-coloured rash + arthritis + ferritin >10,000 ng/mL. Seronegative. Can be fatal if untreated
- Diagnosing RA based on RF alone โ RF is positive in SLE, Sjรถgren’s, HCV, SBE, and 5% of normals. Always confirm with anti-CCP + clinical criteria
- Missing seronegative RA โ ~10% of RA has negative RF AND anti-CCP. Clinical synovitis + criteria = diagnosis
- Attributing all joint pain in RA to the disease โ RA patients get OA, gout, septic arthritis, AVN (from steroids). Investigate each new complaint
- Waiting for erosions before starting DMARDs โ Erosions are irreversible. Treat EARLY and aggressively
- Fibromyalgia co-existing with RA โ Pain out of proportion to joint count? Consider FM overlay โ avoid escalating DMARDs inappropriately
- RA spares DIP joints โ DIP involvement = OA (Heberden’s), PsA, or erosive OA
- Single hot joint in RA patient on biologics = septic arthritis until aspirated
- Jaccoud’s arthropathy (SLE) = reducible; RA deformities are fixed
- “Pencil in cup” deformity on X-ray = Psoriatic Arthritis
- RS3PE = pitting oedema of hands + seronegative symmetric synovitis + elderly โ rule out malignancy
- A. Treatment aimed at best care; must involve shared decision-making
- B. Decisions based on disease activity, safety, comorbidities, and structural progression
- C. Rheumatologists are the primary specialists caring for RA patients
- D. Access to multiple DMARDs with different mechanisms is required (heterogeneity of RA)
- E. RA incurs high individual, medical, and societal costs โ consider in management
If โฅ50% improvement at 3 months AND target reached at 6 months โ Continue Phase I ยฑ dose reduction in sustained remission. If NOT โ Proceed to Phase II.
Previous versions stratified patients by risk factors (RF+, erosions, high disease activity) to guide Phase II choice. The 2025 task force removed this stratification โ MTX failure alone is now sufficient indication for bDMARD. This reflects declining biosimilar costs and evidence that second csDMARD has poor persistence.
| Drug | Class | Dose / Route | Key Points |
|---|---|---|---|
| Adalimumab | Anti-TNF | 40 mg SQ every 2 weeks | Biosimilars widely available; most used globally |
| Etanercept | Anti-TNF (TNF-R fusion) | 50 mg SQ weekly or 25 mg biweekly | Approved as monotherapy; less TB reactivation risk |
| Infliximab | Anti-TNF | 3 mg/kg IV at 0,2,6 weeks, then q8w | IV; can increase dose to 10 mg/kg |
| Certolizumab pegol | Anti-TNF (PEGylated Fab) | 400 mg SQ at 0,2,4 weeks; then 200 mg q2w | Safe in pregnancy (no placental transfer) |
| Golimumab | Anti-TNF | 50 mg SQ monthly | Monthly dosing โ convenience |
| Tocilizumab | Anti-IL-6R | 4โ8 mg/kg IV monthly OR 162 mg SQ q1โ2w | Good for RA-ILD; CRP unreliable for monitoring |
| Sarilumab | Anti-IL-6R | 200 mg SQ every 2 weeks | Monotherapy approved; good if can’t use csDMARD |
| Abatacept | CTLA4-Ig (T-cell co-stimulation blocker) | Weight-based IV monthly OR 125 mg SQ weekly | Good safety profile; preferred in chronic lung disease |
| Rituximab | Anti-CD20 (B-cell depletion) | 1000 mg IV ร 2 doses (day 0 and 14); repeat q24w | Preferred in: seronegative + lymphoma history + HCV; risk of PML |
| Anakinra | IL-1RA | 100 mg SQ daily | Less efficacious; used for AOSD, Muckle-Wells, Still’s |
JAKi are at the same algorithmic level as bDMARDs but require careful risk assessment. Use with caution in patients with: age >65, current or past smoking, other CV risk factors (diabetes, obesity, HTN), history of malignancy, prior thrombosis, history of NMSC, or taking hormonal contraceptives. Based on ORAL Surveillance trial (tofacitinib vs anti-TNF in high-CV risk RA): โMACE, โmalignancy, โVTE risk. Most observational data have NOT consistently confirmed these risks โ use clinical judgment.
| Drug | JAK Selectivity | Dose | Monitoring |
|---|---|---|---|
| Tofacitinib | JAK1/JAK3 (minor JAK2) | 5 mg PO twice daily OR 11 mg extended-release once daily | CBC, LFTs, lipids; check lipids at 4โ8 weeks |
| Baricitinib | JAK1/JAK2 | 4 mg PO once daily (2 mg if renal impairment/elderly) | Same as tofacitinib; watch platelets (JAK2 inhibition) |
| Upadacitinib | Preferential JAK1 | 15 mg PO once daily | CBC, LFTs, lipids; herpes zoster prophylaxis in high-risk |
| Filgotinib | Preferential JAK1 | 200 mg PO once daily | Spermatogenesis concern (avoid in men trying to conceive) |
All JAKi: Contraindicated in pregnancy. Screen for latent TB before starting. Risk of herpes zoster โ consider prophylaxis. Check VTE risk.
- If anti-TNF fails: Switch to another anti-TNF OR different class (abatacept, rituximab, IL-6Ri, JAKi)
- If 1 TNF inhibitor fails: Second anti-TNF is a valid option (class switch not mandatory)
- If primary failure (no response): Prefer switching to a different mechanism of action
- If secondary failure (loss of response after initial benefit): Causes include immunogenicity, inadequate dosing, adherence โ TDM can help (though EULAR 2025 states TDM is NOT routinely needed)
- Cycling between JAKi after JAKi failure: Positive observational data โ acceptable approach
Previous EULAR recommended “consider stopping” in remission. 2025 update strengthened this: Stopping DMARDs leads to flares in the vast majority within 1 year. New language: Continue DMARDs but dose reduction/interval increase may be considered after โฅ6 months of sustained remission. GCs must be discontinued before tapering advanced therapy.
Tapering hierarchy: First taper GC โ then taper/space bDMARD or JAKi โ lastly taper csDMARD (MTX). Never abruptly stop.
| Drug | Dose | Serious Toxicities | Initial Eval | Monitoring |
|---|---|---|---|---|
| Hydroxychloroquine | 200โ400 mg/day (โค5 mg/kg) | Irreversible retinal damage, cardiotoxicity, blood dyscrasia | Eye exam if >40 yrs | Optical coherence tomography yearly |
| Sulfasalazine | 500 mg twice daily โ 1โ1.5 g twice daily | Granulocytopenia, haemolytic anaemia (G6PD def) | CBC, LFTs, G6PD | CBC q2โ4w ร 3 months, then q3 months |
| Methotrexate | 10โ25 mg/week PO/SQ + folic acid 5 mg/week | Hepatotoxicity, myelosuppression, ILD, teratogen (Preg Cat X) | CBC, LFTs, creatinine, CXR, viral hepatitis panel | CBC + LFTs q4โ6w initially, then q8โ12w |
| Leflunomide | 10โ20 mg/day | Hepatotoxicity, myelosuppression, teratogen (X), peripheral neuropathy | CBC, LFTs, viral hepatitis panel | CBC + LFTs q2โ3 months |
| Anti-TNF agents | (See above) | โBacterial infections, TB reactivation, โlymphoma risk (controversial), drug-induced lupus, demyelination | TB screening, hepatitis B/C, CBC | LFTs periodically; watch injection site reactions |
| Abatacept | Weight-based IV or 125 mg SQ weekly | โBacterial/viral infections | TB screening | Monitor infusion reactions |
| Rituximab | 1000 mg IV ร 2 (0 and 14 days); repeat q24w | โInfections, infusion reactions, PML (rare), HBV reactivation | CBC, viral hepatitis panel | CBC regularly; consider prophylaxis |
| Tocilizumab | 4โ8 mg/kg IV monthly OR 162 mg SQ q1โ2w | Infections, โLFTs, neutropenia, dyslipidaemia | TB screening, LFTs, CBC, lipids | CBC, LFTs at regular intervals; lipids |
| JAK inhibitors | (See above) | โInfections, herpes zoster, MACE (tofacitinib high-risk), VTE, dyslipidaemia, malignancies (long-term) | TB screening, CBC, LFTs, lipids, creatinine | CBC, LFTs, lipids at regular intervals |
๐คฐ Pregnancy
- RA often improves in pregnancy (75% of women) but flares postpartum
- Safe: Hydroxychloroquine, sulfasalazine (+ folate), low-dose prednisone, certolizumab pegol (no placental transfer โ preferred biologic in pregnancy)
- Contraindicated: MTX (Category X โ stop 3 months before conception), leflunomide (Category X โ need washout with cholestyramine), all JAK inhibitors
- Anti-TNF (except certolizumab) โ consider risk/benefit; generally safe through 2nd trimester; avoid in 3rd trimester due to placental transfer
๐ด Elderly Patients (>65 years)
- Same efficacy of conventional DMARDs and biologics; increased infection risk
- MTX dose may need adjustment for declining renal function (avoid if CrCl <30)
- JAKi with extra caution in elderly (higher baseline CV/malignancy risk)
- Fall risk โ bone protection mandatory if on GC; FRAX calculation
๐ซ RA-ILD
- Avoid MTX and leflunomide in established ILD (lung toxicity risk)
- Preferred DMARDs: Hydroxychloroquine, abatacept (may slow ILD progression), rituximab
- EULAR 2025: Nintedanib may slow lung function decline in RA-ILD (subanalyses of INBUILD trial) โ consult pulmonology
๐ Before Starting Biologics/JAKi โ Mandatory Pre-treatment Screening
- TB screening: QuantiFERON Gold or Mantoux; if positive โ treat latent TB (isoniazid 9 months) THEN start biologic
- Hepatitis B/C serology; HBsAg+ โ antiviral prophylaxis before anti-TNF/rituximab
- Live vaccines: Administer all live vaccines โฅ4 weeks BEFORE starting biologics; NO live vaccines WHILE on biologics
- NMSC screening before JAKi (slightly elevated risk)
- Exercise: Dynamic strength training + aerobic (150 min/week moderate intensity) โ reduces DAS28, improves HAQ and cardiovascular risk
- Physiotherapy: Range of motion exercises, splinting (night splints for wrists), adaptive devices, joint protection education
- Occupational Therapy: Joint protection strategies, assistive devices (jar openers, raised toilet seats), vocational adaptation
- Smoking cessation: Reduces disease activity, improves DMARD response, lowers CV risk
- Diet: Mediterranean diet โ anti-inflammatory; omega-3 supplementation may modestly help; avoid obesity (increases inflammatory load)
- Psychological support: CBT for pain management; depression screening (PHQ-9); support groups
- Foot orthotics: For MTP subluxation, valgus deformities; custom insoles reduce foot pain and improve gait
- Total joint replacement (hip, knee, shoulder) โ severe erosive disease with refractory pain and functional impairment; hip/knee most commonly
- Synovectomy โ chronic synovitis unresponsive to medical therapy in a single joint
- Tendon repair โ extensor tendon rupture (little finger โ 4th โ 3rd); early repair gives better results
- Wrist arthrodesis โ severe wrist destruction with pain; sacrifices motion but eliminates pain
- C1-C2 fusion โ atlantoaxial subluxation with myelopathy
- MCP arthroplasty โ silicone implants for severe MCP destruction
- MTX mechanism: Inhibits DHFR โ folate antagonism โ anti-inflammatory; always give folic acid with it
- EULAR 2025: Remove prognostic stratification โ MTX failure = go to bDMARD
- Certolizumab pegol = safest anti-TNF in pregnancy (no Fc portion โ no transplacental transfer)
- Latent TB must be treated before starting any biologic
- In sustained remission: Taper, do NOT stop โ stopping โ flare in most patients within 1 year
- Triple therapy (MTX + SSZ + HCQ) is not recommended per EULAR 2025 โ no proven superiority over MTX + GC; worse radiographic outcomes
Interpretation: >5.1 = High disease activity | 3.2โ5.1 = Moderate | 2.6โ3.2 = Low | <2.6 = Remission
โ ๏ธ Limitation: CRP/ESR blunted by IL-6R inhibitors and JAKi โ DAS28 may overestimate remission. Prefer CDAI or SDAI with these drugs. DAS28 weighted on tender joints (subjective) โ fibromyalgia can falsely elevate it.
Interpretation: >22 = High | 10โ22 = Moderate | 2.8โ10 = Low | โค2.8 = Remission
โ No labs required โ bedside calculation. Not affected by IL-6R inhibitor. Preferred in clinical practice.
ALL 4 criteria must be met simultaneously โ most stringent definition. OR SDAI โค3.3. Preferred definition for clinical trials and guideline endpoints (Per EULAR 2025 and 2022 ACR/EULAR revision).
0 = No disability |
1 = Mild |
2 = Moderate |
3 = Severe disability
Primary measure of functional disability and response in clinical trials
| Drug | Baseline Tests | Monitoring Frequency | Key Toxicity to Watch |
|---|---|---|---|
| MTX | CBC, LFTs, creatinine, CXR, HBV/HCV, beta-hCG | Monthly ร 6 months โ q6โ12 weeks | Hepatotoxicity, myelosuppression, pneumonitis (stop if ILD worsens) |
| Leflunomide | CBC, LFTs, HBV/HCV | Monthly ร 6 months โ q2โ3 months | Hepatotoxicity, peripheral neuropathy; cholestyramine washout if pregnant |
| Sulfasalazine | CBC, LFTs, G6PD level | q2โ4w ร 3 months โ q3 months | Granulocytopenia, haemolytic anaemia (G6PD deficient) |
| Hydroxychloroquine | Eye exam baseline (if >40 or prior eye disease) | Annual OCT + visual field testing | Irreversible macular retinopathy (dose >5 mg/kg; duration >5 years = risk) |
| Anti-TNF | TB screening, HBV/HCV, CBC, ANA | LFTs periodically; CBC if symptoms | TB reactivation, serious bacterial infections, demyelination, drug-induced lupus |
| Rituximab | CBC, HBV/HCV, Quantiferon | CBC at regular intervals; IgG levels | PML (JC virus), HBV reactivation, persistent B-cell depletion |
| Tocilizumab | TB, CBC, LFTs, lipids | LFTs, CBC, lipids regularly | LFT elevation, neutropenia, bowel perforation (GI pathology history) |
| JAK inhibitors | TB, CBC, LFTs, lipids, creatinine | CBC, LFTs, lipids q4โ8w initially โ regularly | Herpes zoster (โ 2-5ร), lipid elevation, VTE, MACE risk (tofacitinib high-CV) |
| Glucocorticoids | BP, BMI, fasting glucose, DEXA if chronic use | BP, glucose periodically; annual DEXA | Osteoporosis, DM, HPA suppression, cataracts, avascular necrosis |
All patients on GC โฅ3 months should receive: Calcium 1000โ1500 mg/day + Vitamin D 800โ2000 IU/day. If prednisone โฅ7.5 mg/day for โฅ3 months AND any fragility fracture OR T-score โค-2.5 โ Add bisphosphonate (alendronate 70 mg weekly or zoledronic acid 5 mg annually). Per ACR 2022 GC-induced osteoporosis guidelines.
| Vaccine | Recommendation | Timing / Notes |
|---|---|---|
| Influenza (inactivated) | โ Recommended annually | Safe on all DMARDs; slightly reduced immunogenicity on MTX, rituximab |
| Pneumococcal (PCV-15/20 + PPSV23) | โ Strongly recommended | Immunocompromised schedule; repeat PPSV23 after 5 years |
| Herpes Zoster (Shingrix โ recombinant subunit) | โ Recommended (esp. on JAKi) | 2 doses 2โ6 months apart; preferred over live Zostavax on immunosuppressants |
| COVID-19 mRNA vaccines | โ Recommended | Hold MTX 1โ2 weeks post-dose if possible (improves immunogenicity); space rituximab and vaccines by โฅ4 weeks |
| Hepatitis B | โ Recommended if seronegative | Complete before starting biologics; use high-dose formulation if on immunosuppressants |
| Live attenuated vaccines (MMR, varicella, nasal flu, Zostavax, yellow fever) | ๐ด CONTRAINDICATED | While on any biologic, JAKi, or significant immunosuppression. Give โฅ4 weeks BEFORE starting or โฅ6 months AFTER rituximab |
- “RA is a lifelong condition, but it is very manageable.” โ Set realistic expectations; emphasize that modern treatments can achieve remission in most patients
- On Methotrexate: “Take it once a week only โ NOT daily. Always take folic acid on the other 6 days. Avoid alcohol. Use effective contraception โ both men AND women โ while on MTX and for 3 months after stopping.”
- On Biologics: “You’ll have a slightly higher infection risk. Get vaccinations updated before starting. Avoid crowded places during flu season. See a doctor immediately if you develop fever, chills, or unusual infections.”
- On Glucocorticoids: “We use these for a short time only. Long-term use causes bone loss, weight gain, diabetes. Never stop them suddenly.”
- Lifestyle: Quit smoking (worsens RA and reduces drug response). Exercise daily โ it’s as important as medication. Mediterranean diet. Maintain healthy weight.
- Morning stiffness: “Warm showers and gentle movement in the morning help. Plan important activities for mid-morning when stiffness has improved.”
- Joint protection: Avoid forceful gripping; use assistive devices; distribute load across larger joints when possible
- When to call immediately: Sudden severe joint pain in one joint (may be infected), fever >38ยฐC, difficulty breathing, sudden neck pain with arm weakness
- Mental health: Depression affects 20โ30% of RA patients. It worsens pain perception and disease outcomes. Ask for help early.
- Monitoring: Regular blood tests are non-negotiable while on DMARDs โ not optional. Even if feeling well, liver/blood tests can be abnormal silently
- DAS28 remission = <2.6; Low disease activity = 2.6โ3.2; Goal = remission (early RA) or at least LDA (established)
- Boolean remission (EULAR 2025): TJCโค1, SJCโค1, CRPโค1 mg/dL, PGAโค2 cm (revised from 1 cm in 2022)
- HCQ retinopathy risk: Duration >5 years AND/OR dose >5 mg/kg/day
- PML with rituximab = JC virus reactivation โ rare but fatal; check JC antibody status before use
- Live vaccines are contraindicated while on biologics/JAKi
RA is a chronic, systemic, autoimmune inflammatory arthritis driven by Th1/Th17 cells and B cells targeting citrullinated peptides (via ACPA), causing progressive joint destruction through TNF-ฮฑ/IL-6/pannus/osteoclast activation, managed with early MTX + GC escalating to bDMARDs/JAKi per a treat-to-target (T2T) strategy aiming for DAS28 <2.6.
- Anti-CCP antibody has ~97% specificity for RA โ the most specific test
- RA is the most common inflammatory arthritis; OA is the most common arthritis overall
- RA SPARES DIP joints and the lumbar spine (unlike OA and SpA respectively)
- Morning stiffness >1 hour = inflammatory (RA); <30 min = degenerative (OA)
- Felty’s syndrome = RA + splenomegaly + neutropenia โ highest lymphoma risk
- Methotrexate is the anchor DMARD; ALWAYS co-prescribe folic acid (5 mg/week) to reduce toxicity
- EULAR 2025: Start DMARDs immediately on diagnosis; target remission within 6 months
- No. 1 cause of death in RA = Cardiovascular disease (CVD risk is 2ร general population)
- Latent TB MUST be treated before starting any biologic DMARD
- Stopping DMARDs in remission leads to flares in most patients within 1 year โ TAPER, don’t stop (EULAR 2025)
| The Trap | The Answer |
|---|---|
| Patient with positive RF + joint pains โ “Diagnose RA” | ๐ด RF alone is NOT diagnostic. 5% of normals are RF+. Need clinical criteria + anti-CCP + exclude mimics |
| RA patient develops acute single hot joint โ “Flare” | ๐ด Aspirate the joint! Septic arthritis must be excluded first โ especially if on biologics/JAKi |
| Patient on MTX stops folic acid because “it blocks MTX” | ๐ด Folic acid does NOT reduce MTX efficacy โ only reduces mucositis, hepatotoxicity, myelosuppression. ALWAYS co-prescribe |
| Prescribing MTX daily instead of weekly | ๐ด MTX in RA is given ONCE WEEKLY. Daily dosing (cancer dosing) causes severe toxicity. Classic prescription error |
| Giving live vaccine to patient starting adalimumab next week | ๐ด Live vaccines must be given โฅ4 weeks BEFORE biologics. Once on biologics = NO live vaccines |
| Patient on tocilizumab with DAS28 <2.6 โ “In remission” | โ ๏ธ IL-6 inhibitors blunt CRP/ESR independently โ DAS28 is unreliable. Use CDAI/SDAI or Boolean criteria |
| “RA is only a joint disease” | ๐ด RA is systemic โ CVD, ILD, vasculitis, lymphoma, renal amyloid, anaemia โ all major EAMs with mortality impact |
| Atlantoaxial subluxation risk only in late disease | ๐ด Can occur at any stage. ALWAYS check C-spine before GA/intubation in RA โ ask about symptoms of myelopathy |
Score calculation: Joint involvement (>10 small joints = 5pts) + Serology (high positive anti-CCP โฅ3รULN = 3pts) + Acute phase reactants (ESR elevated = 1pt) + Duration โฅ6 weeks (1pt) = 10/10 (or 8 if only 4โ10 small joints; 3pt serology + 1pt APR + 1pt duration + 3pt joints = 8). Score โฅ6 = Definite RA. Per EULAR 2025 Rec #1: Start DMARDs immediately. MTX is first-line (Rec #4). Anti-TNF is Phase II โ not first-line. HCQ alone is inadequate for established RA.
Anti-TNF agents (especially infliximab and adalimumab, which are monoclonal antibodies) cause reactivation of latent TB by impairing granuloma integrity โ TNF-ฮฑ is essential for granuloma maintenance. Even if the QuantiFERON was negative (10โ15% false negative rate), the clinical picture of upper lobe cavitating disease + constitutional symptoms in a patient on anti-TNF is TB until proven otherwise. The error: A single negative QuantiFERON does not fully exclude latent TB. IGRA has a false-negative rate, especially in immunocompromised patients. Some guidelines recommend Mantoux AND QuantiFERON together. Adalimumab must be STOPPED immediately; anti-TB treatment initiated. Adalimumab can be resumed after 2 months of adequate anti-TB therapy in most guidelines.
| Feature | RA | OA | PsA | SLE Arthritis |
|---|---|---|---|---|
| Morning stiffness | >1 hour | <30 min | Variable | Variable |
| Joints affected | MCP, PIP, Wrist, MTP | DIP, 1st CMC, Hip, Knee | DIP (sausage digit), Sacroiliac | MCP, PIP, Wrist (similar to RA) |
| DIP involvement | โ Spared | โ Heberden’s nodes | โ Classic | โ Usually spared |
| Synovitis type | Boggy (synovial fluid) | Hard/bony (osteophytes) | Synovitis + Enthesitis | Jaccoud’s (reducible, non-erosive) |
| Serology | RF+, Anti-CCP+ (70%, 67%) | Negative | RF negative (seronegative) | ANA+, anti-dsDNA+, low C3/C4 |
| X-ray | Erosions, periarticular osteopenia | Osteophytes, sclerosis | “Pencil in cup”; fluffy periostitis | No erosions (Jaccoud’s) |
| Skin | Nodules, purpura | None | Psoriasis, nail pitting, onycholysis | Malar rash, photosensitivity, discoid |
| Systemic features | Common (ILD, CVD, etc.) | Absent | Uveitis, IBD, psoriasis | Nephritis, seizures, serositis |
| First-line Rx | MTX + GC | NSAIDs, Paracetamol, Physio | MTX (skin+joints); anti-TNF (severe) | HCQ + MTX; lupus-specific |
Each level contains representative questions. Click any level header to expand. All questions include correct answer, detailed explanation (โฅ3 lines), and a teaching point. Tags: [Topic] [Bloom’s Level] [Difficulty].
Anti-CCP (ACPA) has a sensitivity of ~67% and specificity of ~97% for RA โ making it the most specific serological test. RF is positive in ~70% of RA patients but also in SLE, Sjรถgren’s, HCV, SBE, and ~5% of normal individuals. ANA is positive in ~30% of RA patients (low titre, non-specific). Anti-dsDNA is specific for SLE, not RA.
RA characteristically involves MCPs, PIPs, wrists, and MTPs symmetrically โ but SPARES DIP joints. DIP involvement is characteristic of Osteoarthritis (Heberden’s nodes) and Psoriatic Arthritis. This is a classic exam discriminator. Remembering the “DIP” joints in RA = Doesn’t Involve Proximally-distal pattern = DIP spared, PIP involved.
Felty’s syndrome is the triad of RA + Splenomegaly + Neutropenia. It occurs in patients with long-standing, typically seropositive (high RF titre) RA. The neutropenia predisposes to serious bacterial infections, and patients with Felty’s syndrome have a 2โ4ร increased risk of developing non-Hodgkin’s B-cell lymphoma. Its incidence has declined significantly with modern DMARD therapy.
MTX inhibits dihydrofolate reductase (DHFR) โ blocks tetrahydrofolate regeneration โ depletes purines and thymidylate โ anti-inflammatory AND anti-proliferative effects. In RA, the anti-inflammatory effect is thought to be largely via adenosine release rather than purely folate inhibition. Supplemental folic acid replenishes the depleted folate pool, reducing mucositis, hepatotoxicity, and myelosuppression, without substantially diminishing the anti-inflammatory effect. Multiple RCTs confirm folic acid supplementation does not reduce MTX clinical efficacy in RA.
IL-6 is the primary driver of the acute phase response in RA โ it stimulates hepatic production of CRP, fibrinogen, serum amyloid A, and other APRs. It also drives the ESR elevation (via fibrinogen). Tocilizumab (IV/SQ) and sarilumab (SQ) are monoclonal antibodies against the IL-6 receptor (IL-6R). They dramatically suppress CRP and ESR, sometimes to below normal โ even without complete clinical remission. This creates the important clinical pitfall: DAS28 (which includes CRP/ESR) underestimates disease activity in patients on IL-6R inhibitors or JAKi.
Per EULAR 2025 Recommendation #4 and #5: MTX should be part of the first treatment strategy. Short-term glucocorticoids should be considered when initiating csDMARDs, used as bridging therapy while MTX takes effect (6โ12 weeks), and tapered as rapidly as clinically feasible. Biologics (anti-TNF) and JAKi are Phase II treatments โ added when Phase I fails at 3โ6 months. No trial has shown superiority of bDMARDs over MTX+GC as initial therapy in early RA. High ACPA titre is a prognostic factor but does NOT change the initial treatment algorithm in EULAR 2025 (prognostic stratification was removed).
Yellow Fever vaccine (Stamaril, YF-Vax) is a live attenuated vaccine โ ABSOLUTELY CONTRAINDICATED in patients on biologics, JAKi, or significant immunosuppression. Live vaccines can cause disseminated infection in immunocompromised patients. This includes: MMR, Varicella/Zoster (Zostavax โ live), Nasal Flu (LAIV), Yellow Fever, Typhoid (live oral Ty21a), BCG. Safe alternatives should be explored: if travel is essential, adalimumab may need to be temporarily held for a sufficient period before vaccination (varies by biologic half-life โ typically 3โ5 half-lives; for adalimumab tยฝ ~14 days โ hold ~5โ10 weeks), consult infectious disease/tropical medicine.
The HRCT pattern described โ bilateral basal ground-glass opacities, subpleural sparing, traction bronchiectasis โ is classic for NSIP (Non-Specific Interstitial Pneumonia), the most common ILD pattern in RA (followed by UIP). UIP (Usual Interstitial Pneumonia) shows honeycombing and lacks subpleural sparing. In RA-ILD, MTX and leflunomide should be avoided/discontinued as both can cause drug-induced pneumonitis that is difficult to distinguish from RA-ILD and can worsen existing ILD. Abatacept has emerging evidence for stabilizing RA-ILD (RECOURSE trial data). Rituximab is also used. EULAR 2025 mentions nintedanib as potentially slowing ILD progression (INBUILD data).
JAK inhibitors, particularly tofacitinib, increase the risk of Herpes Zoster reactivation by 2โ5ร compared to background RA risk. JAK1/JAK3 inhibition impairs IFN-ฮณ signaling and lymphocyte surveillance, reducing control over latent VZV. Treatment: oral valaciclovir or aciclovir (adjust dose for renal function). Tofacitinib should be held during active zoster. Prevention: Shingrix (recombinant zoster vaccine, 2 doses) is recommended BEFORE starting JAKi in patients โฅ50 years or those at high risk. Shingrix is a recombinant (non-live) vaccine โ SAFE with JAKi (unlike live Zostavax).
MTX must be stopped immediately โ it is a known teratogen (FDA Pregnancy Category X / FKSH Teratogen Class D). Risk: fetal loss, neural tube defects, craniofacial abnormalities. If MTX is stopped at 8 weeks gestation: the fetus has already been exposed during organogenesis โ urgent obstetric and geneticist consultation is needed. Leflunomide is also Category X โ absolutely contraindicated. Safe in pregnancy: Hydroxychloroquine (antimalarial; continue throughout pregnancy), sulfasalazine (+ high-dose folic acid), low-dose prednisolone, certolizumab pegol (preferred biologic โ no placental transfer). About 75% of RA patients improve during pregnancy; but 90% flare postpartum. Continue certolizumab throughout pregnancy if needed โ no neonatal immunosuppression (no IgG to cross placenta).
Per EULAR 2025 Recommendation #6: “JAK inhibitors may be considered, but pertinent risk factors must be taken into account.” The footnote to the EULAR 2025 algorithm specifically lists: Age >65, current/past smoking, history of cardiovascular events (MACE), history of malignancy, history of NMSC, thromboembolic risk factors, and taking hormonal contraceptives as factors precluding preferential JAKi use. This patient has multiple contraindications to JAKi (age 68, smoker, recent MI). bDMARDs are preferred. Abatacept may be particularly appropriate in an elderly patient with CV disease given its good tolerability profile. Triple therapy was removed from EULAR 2025 recommendation (no superiority over MTX+GC; worse radiographic outcomes in NORD-STAR data).
Per EULAR 2025 Recommendation #9: “After glucocorticoids have been discontinued and a patient is in sustained remission, continuation of DMARDs is recommended, but dose reduction may be considered.” This represents a significant strengthening of the 2022 recommendation. Data consistently show that stopping DMARDs (both csDMARDs and bDMARDs) in remission leads to flares in the vast majority of patients within 12 months (PRESERVE, STRASS, OPTIMA trials). Dose reduction/interval extension is acceptable and may reduce costs and side effects while maintaining remission. The hierarchy: taper GC first (already done), then space bDMARD (e.g., adalimumab every 3 weeks, then monthly), lastly reduce MTX dose. Never stop everything simultaneously.
Peptidylarginine Deiminase type 4 (PAD4) is encoded by the PADI4 gene and catalyzes the post-translational modification of arginine โ citrulline (citrullination/deimination) in cellular proteins. This creates neo-antigens (fibrinogen, vimentin, ฮฑ-enolase, collagen type II, keratin) โ the targets of ACPA. PAD4 is upregulated by cigarette smoking, hypoxia, and infection (especially P. gingivalis). PADI4 polymorphisms are associated with a 2ร RA risk (mainly in East Asian populations). PAD inhibitors (e.g., BB-Cl-amidine, GSK199) are under investigation as therapeutic agents that could interrupt the earliest step of RA pathogenesis โ the generation of citrullinated neoantigens โ potentially preventing ACPA formation itself.
In EULAR 2022, patients failing Phase I (MTX+GC) were stratified: those WITH adverse prognostic factors (high disease activity, seropositive RF/ACPA, early erosions, failure of 2+ csDMARDs) went directly to bDMARD (old recommendation 8); those WITHOUT risk factors could try another csDMARD first (old recommendation 7). In EULAR 2025, this stratification was abolished. Reasons: (1) MTX failure itself carries poor prognosis regardless of baseline markers; (2) Low persistence rates of second csDMARD after MTX failure (low efficacy, high dropout โ Erhardt DP et al, Arthritis Care Res 2019); (3) Evidence that adding csDMARD after MTX failure has much lower persistence than adding a bDMARD; (4) Biosimilar costs have fallen dramatically, making bDMARDs economically comparable to second csDMARD strategies in many health systems; (5) Generic tofacitinib now available. Result: All patients failing MTX+GC should proceed to bDMARD (Phase II) rather than trying another csDMARD round first. 98% of task force voted in favour of this change.
- ๐ EULAR 2025 RA Management Recommendations โ Smolen JS et al. Annals of the Rheumatic Diseases 2026;85:991โ1009
- ๐ 2010 ACR/EULAR Classification Criteria for RA โ Aletaha D et al. Arthritis Rheum 2010;62:2569โ2581
- ๐ ACR 2021 Guideline for Treatment of RA โ Fraenkel L et al. Arthritis Care Res 2021;73:924โ939
- ๐ Harrison’s Principles of Internal Medicine, 21e โ Chapter 358: Rheumatoid Arthritis (Ankoor Shah, E. William St. Clair)
- ๐งฎ MDCalc DAS28 Calculator โ mdcalc.com/das28 (also: CDAI, SDAI, 2010 ACR/EULAR criteria)
- ๐ EULAR Vaccination Recommendations for Autoimmune Inflammatory Diseases โ Ann Rheum Dis 2023
- ๐ฌ StatPearls โ Rheumatoid Arthritis 2023 โ NCBI Bookshelf
You have completed the Rheumatoid Arthritis Masterclass. You now understand the molecular pathogenesis, the full clinical spectrum, how to apply 2010 ACR/EULAR classification criteria, the EULAR 2025 three-phase treatment algorithm, drug monitoring schedules, and can answer questions from Foundation to Fellowship level. Review the flashcards weekly, attempt the quiz at each level, and revisit this module before clinical rotations and board exams.
